Company Analysis
Sign in

Xeris Biopharma Holdings, Inc. (XERS)

Nasdaq: XERS · Pharmaceutical Preparations · Chicago, IL · filing with the SEC since 2021
Full chart Alerts Compare
Grade5.9
◀ Past 7.3● Present 5.4▶ Future 5.1
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

32 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Xeris Biopharma Holdings, Inc.’s names, not what it holds today.

Patents granted
32
32 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 2 in 2024 and 3 in 2023
Applications published
42
2 of them in 2025
Names they are printed under
4
a subsidiary
By yearGrantedApplications published
'07'11'12'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals9
Medical technology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
XERIS PHARMACEUTICALS, INC. a subsidiary
US, as the owner printed on each patent
25 granted
23 published
Xeris Pharmaceuticals, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
17 published
Cortendo AB a subsidiary
SE, as the owner printed on each patent
7 granted
1 published
Strongbridge Biopharma plc a subsidiary
named as the applicant on its applications, in IE
0 granted
1 published
Names not counted (4)
Strongbridge Dublin Limited
Most of its patents print US; this name counts in IE. 0 granted and 29 published under it are not counted.
Strongbridge Dublin Limited
Most of its patents print US; this name counts in IE. 9 granted and 4 published under it are not counted.
Cortendo AB
Most of its patents print US; this name counts in SE. 0 granted and 10 published under it are not counted.
Cortendo AB
Most of its patents print US; this name counts in SE. 3 granted and 1 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Aug 5, 202512,377,096Methods of treating disease with levoketoconazolePharmaceuticalsXERIS PHARMACEUTICALS, INC.
Apr 23, 202411,964,003Stable sustained release therapeutic compositions in aprotic polar solvents and methods of manufacturing the samePharmaceuticalsXERIS PHARMACEUTICALS, INC.
Apr 16, 202411,957,736Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the samePharmaceuticalsXERIS PHARMACEUTICALS, INC.
Dec 5, 202311,833,157Precipitation resistant small molecule drug formulationsPharmaceuticalsXERIS PHARMACEUTICALS, INC.
Feb 28, 202311,590,205Methods for producing stable therapeutic glucagon formulations in aprotic polar solventsPharmaceuticalsXERIS PHARMACEUTICALS, INC.
Feb 14, 202311,576,951Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the samePharmaceuticalsXERIS PHARMACEUTICALS, INC.
Sep 20, 202211,446,310Stable formulations for parenteral injection of small molecule drugsPharmaceuticalsXERIS PHARMACEUTICALS, INC.
Sep 28, 202111,129,940Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastesMedical technologyXERIS PHARMACEUTICALS, INC.
Jun 1, 202111,020,403Precipitation resistant small molecule drug formulationsPharmaceuticalsXERIS PHARMACEUTICALS, INC.
Apr 27, 202110,987,399Stable formulations for parenteral injection of peptide drugsPharmaceuticalsXERIS PHARMACEUTICALS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0387389METHODS OF TREATING DISEASE WITH LEVOKETOCONAZOLEPharmaceuticalsXERIS PHARMACEUTICALS, INC.
Feb 20, 20252025/0057797STABLE LEVOTHYROXINE COMPOSITIONS IN APROTIC POLAR SOLVENTSPharmaceuticalsXERIS PHARMACEUTICALS, INC.
Oct 17, 20242024/0342249METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTSPharmaceuticalsXERIS PHARMACEUTICALS, INC.
Sep 26, 20242024/0316158STABLE THERAPEUTIC COMPOSITIONS IN APROTIC POLAR SOLVENTS AND METHODS OF MANUFACTURING THE SAMEPharmaceuticalsXERIS PHARMACEUTICALS, INC.
Jul 18, 20242024/0238381STABLE SUSTAINED RELEASE THERAPEUTIC COMPOSITIONS IN APROTIC POLAR SOLVENTS AND METHODS OF MANUFACTURING THE SAMEPharmaceuticalsXERIS PHARMACEUTICALS, INC.
Jun 27, 20242024/0207365METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTSPharmaceuticalsXERIS PHARMACEUTICALS, INC.
May 9, 20242024/0148680STABLE LEVOTHYROXINE COMPOSITIONS IN APROTIC POLAR SOLVENTSPharmaceuticalsXERIS PHARMACEUTICALS, INC.
May 9, 20242024/0148678SUSTAINED RELEASE INJECTABLE THERAPEUTIC FORMULATIONS USING APROTIC POLAR SOLVENTSPharmaceuticalsXERIS PHARMACEUTICALS, INC.
Feb 8, 20242024/0041984METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTSPharmaceuticalsXERIS PHARMACEUTICALS, INC.
Jan 18, 20242024/0016898TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETESPharmaceuticalsXERIS PHARMACEUTICALS, INC.
What it applied for, 2024 to 2025: Pharmaceuticals 10.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton XERS · research, not advice